MeSH term
Frequency | Condition_Probility | Genetic Markers | 16 | 0.0 |
*Genetics, Population | 25 | 6.0 |
Genotype | 69 | 0.0 |
HLA-DQ Antigens/genetics | 28 | 10.0 |
Humans | 244 | 0.0 |
Likelihood Functions | 4 | 2.0 |
Mexico | 2 | 2.0 |
Polymorphism, Genetic | 22 | 0.0 |
Research Support, Non-U.S. Gov't | 127 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 8 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 29 | 0.0 |
Tandem Repeat Sequences/*genetics | 2 | 2.0 |
Exons | 4 | 0.0 |
Male | 92 | 0.0 |
Nucleic Acid Hybridization | 8 | 0.0 |
Sperm Motility/genetics | 2 | 66.0 |
*Alleles | 36 | 2.0 |
Turkey | 4 | 2.0 |
Adolescent | 36 | 0.0 |
Age Factors | 2 | 0.0 |
Child | 41 | 0.0 |
Child, Preschool | 24 | 0.0 |
Female | 93 | 0.0 |
Gene Frequency | 53 | 1.0 |
HLA-DQ Antigens/*genetics | 132 | 34.0 |
Haplotypes | 30 | 1.0 |
Homozygote | 11 | 0.0 |
Infant | 13 | 0.0 |
Phenotype | 10 | 0.0 |
Sex Factors | 2 | 0.0 |
Comparative Study | 39 | 0.0 |
Genes, MHC Class II | 3 | 1.0 |
Genetic Predisposition to Disease | 24 | 1.0 |
Italy | 5 | 0.0 |
Adult | 64 | 0.0 |
Asian Continental Ancestry Group/*genetics | 7 | 2.0 |
China/ethnology | 5 | 2.0 |
English Abstract | 26 | 0.0 |
Ethnic Groups/*genetics | 6 | 3.0 |
Linkage (Genetics) | 5 | 0.0 |
*Polymorphism, Genetic | 19 | 0.0 |
DNA/*genetics | 7 | 2.0 |
*Gene Frequency | 27 | 5.0 |
Alleles | 103 | 1.0 |
Base Sequence | 57 | 0.0 |
DNA Primers | 9 | 0.0 |
Histocompatibility Testing/*methods | 4 | 2.0 |
Molecular Sequence Data | 60 | 0.0 |
Polymerase Chain Reaction | 86 | 0.0 |
Asian Continental Ancestry Group/genetics | 6 | 1.0 |
China | 7 | 1.0 |
*Genetic Predisposition to Disease | 6 | 0.0 |
HLA-DR Antigens/*genetics | 14 | 2.0 |
Polymerase Chain Reaction/methods | 10 | 0.0 |
HLA Antigens/*genetics | 7 | 0.0 |
Aged | 15 | 0.0 |
Hypertension/*genetics | 2 | 1.0 |
Middle Aged | 33 | 0.0 |
Abortion, Habitual/genetics/*immunology | 2 | 20.0 |
Pregnancy | 13 | 0.0 |
*Polymorphism, Restriction Fragment Length | 12 | 1.0 |
Costa Rica | 2 | 15.0 |
Chi-Square Distribution | 5 | 0.0 |
Gene Frequency/genetics | 3 | 0.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
HLA-D Antigens/*genetics | 9 | 6.0 |
HLA-DR Antigens/genetics | 19 | 4.0 |
Haplotypes/genetics | 5 | 0.0 |
Histocompatibility Antigens Class II/*genetics | 7 | 3.0 |
Odds Ratio | 3 | 0.0 |
China/epidemiology | 2 | 1.0 |
HLA-DQ Antigens | 2 | 6.0 |
HLA-DR Antigens | 2 | 0.0 |
Registries/statistics & numerical data | 2 | 15.0 |
Treatment Outcome | 4 | 0.0 |
Blood Stains | 5 | 22.0 |
Sequence Analysis, DNA/methods | 2 | 2.0 |
Templates, Genetic | 2 | 1.0 |
*DNA Fingerprinting | 6 | 13.0 |
Databases, Factual | 3 | 1.0 |
Reference Values | 9 | 0.0 |
*Blood Stains | 2 | 5.0 |
Forensic Medicine/methods | 6 | 17.0 |
Gene Amplification | 10 | 1.0 |
Japan | 11 | 0.0 |
Risk Factors | 14 | 0.0 |
Case-Control Studies | 12 | 0.0 |
Microsatellite Repeats/*genetics | 2 | 0.0 |
Peru | 2 | 4.0 |
*Polymorphism, Single-Stranded Conformational | 2 | 1.0 |
*Restriction Mapping | 2 | 5.0 |
Sensitivity and Specificity | 6 | 0.0 |
Variation (Genetics) | 4 | 0.0 |
Flow Cytometry | 2 | 0.0 |
HLA-DQ Antigens/*analysis/genetics | 5 | 31.0 |
Polymerase Chain Reaction/*methods | 8 | 1.0 |
Reproducibility of Results | 3 | 0.0 |
Animals | 10 | 0.0 |
Prevalence | 2 | 0.0 |
DNA Fingerprinting | 5 | 4.0 |
Forensic Medicine | 4 | 6.0 |
India | 4 | 1.0 |
Histocompatibility Testing/methods | 4 | 9.0 |
Infant, Newborn | 6 | 0.0 |
Blood | 2 | 1.0 |
Dental Enamel Proteins/genetics | 2 | 18.0 |
African Continental Ancestry Group/*genetics | 7 | 2.0 |
Age of Onset | 9 | 0.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 9 | 16.0 |
HLA-DQ Antigens/classification/*genetics | 6 | 40.0 |
HLA-DQ Antigens/*genetics/immunology | 7 | 26.0 |
Histocompatibility Testing | 20 | 2.0 |
DNA/*analysis | 13 | 6.0 |
Forensic Medicine/*methods | 4 | 12.0 |
Polymorphism, Restriction Fragment Length | 20 | 0.0 |
Sequence Analysis/methods | 2 | 25.0 |
*Genetic Markers | 5 | 1.0 |
Glycophorin/genetics | 2 | 20.0 |
Receptors, LDL/genetics | 2 | 2.0 |
Spain/ethnology | 2 | 6.0 |
Vitamin D-Binding Protein/genetics | 3 | 11.0 |
DNA Fingerprinting/methods | 11 | 17.0 |
Discriminant Analysis | 3 | 3.0 |
Gene Frequency/*genetics | 6 | 4.0 |
Genetic Markers/genetics | 5 | 1.0 |
Minisatellite Repeats/*genetics | 4 | 5.0 |
Polymorphism, Genetic/genetics | 3 | 0.0 |
Biological Markers | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Diabetes Mellitus, Type 1/*genetics | 7 | 3.0 |
*Genotype | 3 | 1.0 |
Prospective Studies | 2 | 0.0 |
Genetics, Population | 6 | 1.0 |
Spain | 4 | 1.0 |
Tandem Repeat Sequences | 2 | 1.0 |
African Continental Ancestry Group/genetics | 3 | 1.0 |
European Continental Ancestry Group/genetics | 8 | 1.0 |
HLA-DQ Antigens/*analysis | 4 | 23.0 |
Diabetes Mellitus, Type 1/*genetics/*immunology | 4 | 18.0 |
Amino Acid Motifs | 2 | 0.0 |
Argentina | 2 | 4.0 |
Autoantibodies/immunology | 3 | 2.0 |
Ethnic Groups/genetics | 6 | 3.0 |
*Genes, MHC Class II | 20 | 6.0 |
Genetic Predisposition to Disease/*genetics | 3 | 0.0 |
HLA-DQ Antigens/genetics/immunology | 3 | 15.0 |
HLA-DR Antigens/chemistry/genetics/immunology | 2 | 100.0 |
Hepatitis, Autoimmune/*genetics/*immunology/physiopathology/therapy | 2 | 100.0 |
Linkage Disequilibrium/genetics | 2 | 1.0 |
Recurrence | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Australia | 2 | 1.0 |
*Histocompatibility Antigens Class II | 2 | 3.0 |
Multiple Sclerosis/*genetics/immunology | 3 | 17.0 |
Brazil | 3 | 1.0 |
European Continental Ancestry Group/*genetics | 7 | 2.0 |
Hong Kong | 2 | 4.0 |
DNA/analysis/genetics | 2 | 1.0 |
Exons/genetics | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 6 | 0.0 |
Sequence Alignment | 5 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Blood Glucose/metabolism | 2 | 0.0 |
C-Peptide/blood | 2 | 1.0 |
Glutamate Decarboxylase/*immunology | 5 | 26.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Disease Susceptibility | 11 | 1.0 |
Chile | 3 | 5.0 |
Haplotypes/*genetics | 3 | 1.0 |
Pedigree | 4 | 0.0 |
Ethnic Groups | 3 | 1.0 |
Amino Acid Sequence | 12 | 0.0 |
Mice | 3 | 0.0 |
Rats | 3 | 0.0 |
Genes, MHC Class II/genetics | 2 | 7.0 |
Microsatellite Repeats | 2 | 0.0 |
Moscow | 2 | 8.0 |
DNA/analysis | 7 | 0.0 |
Glycophorin/*genetics | 6 | 21.0 |
Receptors, LDL/*genetics | 6 | 3.0 |
Diabetes Mellitus, Type 1/ethnology/*genetics/immunology | 2 | 100.0 |
New Jersey | 2 | 33.0 |
Glucans/*genetics | 2 | 50.0 |
Reagent Kits, Diagnostic | 2 | 1.0 |
Vitamin D-Binding Protein/*genetics | 4 | 6.0 |
Genes, MHC Class II/*genetics | 4 | 5.0 |
HLA-DP Antigens/genetics | 7 | 14.0 |
Hair/chemistry | 2 | 28.0 |
*Evolution | 2 | 1.0 |
DNA/isolation & purification | 2 | 1.0 |
Mutation | 3 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Time Factors | 4 | 0.0 |
Genetic Heterogeneity | 3 | 1.0 |
Genetic Markers/*genetics | 3 | 2.0 |
Continental Population Groups/genetics | 3 | 3.0 |
Repetitive Sequences, Nucleic Acid/*genetics | 3 | 2.0 |
United States | 4 | 0.0 |
Incidence | 4 | 0.0 |
World Health Organization | 2 | 2.0 |
*Helicobacter pylori/isolation & purification | 2 | 20.0 |
Linkage Disequilibrium | 3 | 0.0 |
Spain/epidemiology | 2 | 1.0 |
*Blood Transfusion | 2 | 1.0 |
Sequence Analysis, DNA/*methods | 2 | 3.0 |
DNA/*blood | 2 | 6.0 |
New York City | 2 | 6.0 |
DNA Primers/chemistry | 2 | 0.0 |
Major Histocompatibility Complex | 3 | 1.0 |
Senegal | 2 | 6.0 |
Risk Assessment | 2 | 0.0 |
HLA-DQ Antigens/analysis | 3 | 6.0 |
HLA-DR Antigens/analysis | 2 | 0.0 |
European Continental Ancestry Group | 6 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Histocompatibility Antigens Class I/*genetics | 4 | 1.0 |
Lymphotoxin/genetics | 2 | 3.0 |
Diabetes Mellitus, Type 1/*immunology | 2 | 2.0 |
Cell Line | 6 | 0.0 |
HLA-DR2 Antigen/genetics | 3 | 16.0 |
*Polymerase Chain Reaction | 8 | 3.0 |
Arabs/*genetics | 2 | 7.0 |
HLA-DR Antigens/*analysis/genetics | 2 | 8.0 |
Heterozygote | 9 | 0.0 |
Indians, North American/*genetics | 2 | 2.0 |
Autoantibodies/*blood | 3 | 1.0 |
Follow-Up Studies | 2 | 0.0 |
Diabetes Mellitus, Type 1/genetics/*immunology | 4 | 8.0 |
Korea | 3 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
DNA/genetics | 10 | 0.0 |
*Mutation | 2 | 0.0 |
Russia | 4 | 4.0 |
Genes, MHC Class II/*immunology | 2 | 10.0 |
HLA-D Antigens/genetics | 3 | 7.0 |
Oligonucleotide Probes | 11 | 1.0 |
Random Allocation | 3 | 0.0 |
Developed Countries | 2 | 40.0 |
*Health Status | 2 | 5.0 |
*Income | 2 | 50.0 |
Life Expectancy | 2 | 4.0 |
*Mortality | 2 | 8.0 |
*Population Surveillance | 2 | 5.0 |
Poverty | 2 | 9.0 |
Socioeconomic Factors | 2 | 1.0 |
World Health | 2 | 3.0 |
Paternity | 3 | 4.0 |
Chromosome Mapping | 8 | 0.0 |
Forensic Anthropology | 2 | 40.0 |
DNA/analysis/*isolation & purification | 2 | 100.0 |
Hair/*chemistry | 3 | 30.0 |
Taiwan | 2 | 1.0 |
Histocompatibility Antigens Class II/genetics | 4 | 3.0 |
DNA Primers/genetics | 2 | 0.0 |
HLA-DP Antigens/*genetics | 3 | 3.0 |
HLA-DR Antigens/*genetics/immunology | 2 | 3.0 |
Disease Susceptibility/immunology | 6 | 8.0 |
Bone Marrow Transplantation/*immunology | 2 | 1.0 |
Heterozygote Detection | 2 | 0.0 |
Blotting, Southern | 6 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Predictive Value of Tests | 3 | 0.0 |
Algeria | 2 | 11.0 |
*Oligonucleotide Probes | 3 | 13.0 |
France | 2 | 0.0 |
DNA | 2 | 0.0 |
Oceanic Ancestry Group/*genetics | 2 | 8.0 |
Terminology | 2 | 1.0 |
Melanins/analysis | 2 | 28.0 |
DNA/genetics/isolation & purification | 3 | 1.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Evolution | 2 | 0.0 |
Poland/epidemiology | 2 | 3.0 |
Colombia | 2 | 4.0 |
DNA Fingerprinting/*methods | 2 | 3.0 |
